New regimen for patients with lymphoma prolongs PFS by up to 28 months

Share This Post

12 Yue days, a study “The Lancet” published online, for CD30 -positive outer peripheral -cell lymphoma patients, this rituximab, cyclophosphamide, doxorubicin and prednisone ( A + CHP ) Better than cyclophosphamide, doxorubicin, vincristine and prednisone ( CHOP ).

Steven Horwitz , MD, from the Memorial Sloan Kettering Cancer Center in New York City and colleagues conducted a double-blind, placebo-controlled, active-control phase 3 study involving 452 patients from 132 locations in 17 countries . These patients CD30- positive peripheral T- cell lymphoma without prior treatment . Patients with 1 : 1 random allocation ratio, accepts A + CHP or of CHOP , sustained 6 , or . 8 th 21 is day cycle.

The researchers found that the median progression-free survival ( PFS ) of the A + CHP group and the CHOP group were 48.2 and 20.8 months, respectively. The incidence of side effects was similar between the two groups, including febrile neutropenia ( 18 % and 15 %, respectively) and peripheral neuropathy ( 52 % and 55 %, respectively). Fatal adverse events occurred in 3 % and 4 % of patients, respectively.

In the CHP to add this cetuximab can improve progression-free and overall survival without increasing toxicity, the study supports the A + CHP for many CD30 positive outer peripheral T new standard treatment for lymphoma patients.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

درمان سرطان در تركيه
Start chat
Need help with cancer treatment?
Scan the code
Welcome to CancerFax !

CancerFax is the most trusted international patient facilitator working with top cancer hospital's in the world like MD Anderson, Dana Farber, Asan, NCC Japan, Sheba, Beijing Cancer Institute and Apollo to bring you best of therapies and drugs.

Let us know what services would you like to avail?

1) Cancer treatment in the USA, Japan, Israel, India, Korea or Singapore?
2) CAR T-Cell therapy treatment
3) Cancer vaccine
4) Online video consultation
5) Proton therapy